Suraksha Diagnostic IPO sees weak response, with 37% subscription; analysts advise avoiding due to high valuation and limited market presence.
The company, whose landmark projects include the New Parliament Building in New Delhi and Atul Setu in Mumbai, derives above 20% of its projects from
The company, which debuted in the unlisted market nearly a year ago at ₹300 apiece, has seen its valuations soar to ₹900 per share. Investment
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003